91 phenotypes from 7 alleles in 13 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Adipoqtm1b(KOMP)Wtsi/Adipoqtm1b(KOMP)Wtsi C57BL/6N-Adipoqtm1b(KOMP)Wtsi/Tcp	abnormal heart morphology	J:211773
	enlarged heart	J:211773
Adipoqtm1b(KOMP)Wtsi/Adipoqtm1b(KOMP)Wtsi C57BL/6NCrl-Adipoqtm1b(KOMP)Wtsi/Tcp	decreased pulmonary ventilation	J:211773
Adipoqtm1Chan/Adipoq+ B6.129-Adipoqtm1Chan	abnormal leukocyte physiology	J:122020
	decreased circulating adiponectin level	J:122020
	increased leukocyte cell number	J:122020
	increased vascular endothelial cell adhesion	J:122020
Adipoqtm1Chan/Adipoqtm1Chan B6.129-Adipoqtm1Chan	abnormal leukocyte physiology	J:122020
	abnormal nitric oxide homeostasis	J:122020
	decreased circulating adiponectin level	J:122020
	decreased fatty acid beta-oxidation	J:79122
	normal homeostasis/metabolism phenotype	J:79122
	increased leukocyte cell number	J:122020
	increased vascular endothelial cell adhesion	J:122020
Adipoqtm1Chan/Adipoqtm1Chan involves: 129S1/Sv * 129X1/SvJ	abnormal lipid homeostasis	J:138678
	abnormal skeletal muscle fiber morphology	J:138678
	increased body weight	J:138678
Adipoqtm1Chan/Adipoqtm1Chan involves: 129S1/Sv * 129X1/SvJ * C57BL/6	albuminuria	J:136297
	fused podocyte foot processes	J:136297
	oxidative stress	J:136297
Adipoqtm1Far/Adipoqtm1Far involves: 129S4/SvJae * C57BL/6J	impaired glucose tolerance	J:111346
	increased body weight	J:111346
	increased circulating glucose level	J:111346
	increased liver triglyceride level	J:111346
	increased percent body fat/body weight	J:111346
	increased susceptibility to diet-induced hepatic steatosis	J:111346
	increased total body fat amount	J:111346
Adipoqtm1Far/Adipoqtm1Far involves: C57BL/6J	impaired glucose tolerance	J:111346
Adipoqtm1Ish/Adipoqtm1Ish involves: 129S7/SvEvBrd * C57BL/6J	abnormal abdominal fat pad morphology	J:199264
	abnormal cardiovascular system morphology	J:106599
	abnormal cardiovascular system physiology	J:106599
	abnormal energy homeostasis	J:199264
	abnormal gas homeostasis	J:199264
	abnormal glucose homeostasis	J:199264
	abnormal hormone level	J:199264
	abnormal lipid level	J:77479
	abnormal osteoblast physiology	J:199264
	abnormal osteoclast morphology	J:199264
	abnormal skeleton morphology	J:199264
	abnormal skeleton physiology	J:199264
	abnormal urine homeostasis	J:199264
	abnormal vascular wound healing	J:79350
	abnormal vasodilation	J:103106
	abnormal white adipose tissue morphology	J:199264
	cardiac hypertrophy	J:106599
	congestive heart failure	J:106599
	decreased body weight	J:199264
	decreased bone mass	J:199264
	decreased bone mineral density	J:199264
	decreased bone ossification	J:199264
	decreased bone trabecula number	J:199264
	decreased food intake	J:199264
	decreased heart rate	J:199264
	decreased insulin secretion	J:199264
	decreased osteoblast cell number	J:199264
	decreased systemic arterial blood pressure	J:199264
	decreased total fat pad weight	J:199264
	decreased trabecular bone volume	J:199264
	decreased ventricle muscle contractility	J:106599
	dilated heart left ventricle	J:106599
	hemorrhage	J:106599
	normal homeostasis/metabolism phenotype	J:199264
	hyperglycemia	J:77479, J:103106
	impaired glucose tolerance	J:199264
	increased adiponectin level	J:199264
	increased bone mass	J:199264
	increased bone mineral density	J:199264
	increased bone ossification	J:199264
	increased bone strength	J:199264
	increased carbon dioxide production	J:199264
	increased circulating adiponectin level	J:199264
	increased circulating free fatty acids level	J:77479
	increased circulating glucose level	J:106599
	increased circulating insulin level	J:77479
	increased circulating osteocalcin level	J:199264
	increased compact bone thickness	J:199264
	increased energy expenditure	J:199264
	increased noradrenaline level	J:199264
	increased osteoblast cell number	J:199264
	increased oxygen consumption	J:199264
	increased susceptibility to diet-induced obesity	J:103106
	increased susceptibility to induced morbidity/mortality	J:106599
	increased systemic arterial systolic blood pressure	J:103106
	increased trabecular bone volume	J:199264
	increased urine adrenaline level	J:199264
	insulin resistance	J:77479
	normal liver/biliary system phenotype	J:199264
	normal muscle phenotype	J:199264
	oxidative stress	J:199264
	pulmonary edema	J:106599
	pulmonary vascular congestion	J:106599
	normal skeleton phenotype	J:199264
vascular restenosis	J:79350
Adipoqtm1Pesch/Adipoqtm1Pesch B6.129S7-Adipoqtm1Pesch	abnormal inguinal fat pad morphology	J:210480
	abnormal respiratory electron transport chain	J:210480
	decreased susceptibility to induced hypothermia	J:210480
	increased core body temperature	J:210480
	increased energy expenditure	J:210480
	increased oxygen consumption	J:210480
Adipoqtm1Pesch/Adipoqtm1Pesch involves: 129S7/SvEvBrd	abnormal gluconeogenesis	J:107486
	impaired glucose tolerance	J:107486
Adipoqtm1Pesch/Adipoqtm1Pesch involves: C57BL/6	maternal effect	J:219264
Adipoqtm1Tka/Adipoq+ involves: 129S4/SvJae * C57BL/6	impaired glucose tolerance	J:77876
	insulin resistance	J:77876
Adipoqtm1Tka/Adipoqtm1Tka involves: 129S4/SvJae * C57BL/6	abnormal vascular wound healing	J:77876
	impaired glucose tolerance	J:77876
	increased circulating triglyceride level	J:77876
	insulin resistance	J:77876
Tg(APOE-Adipoq)#Kry/0 involves: 129 * C57BL/6J	decreased bone mass	J:199264
	decreased bone ossification	J:199264
	decreased circulating osteocalcin level	J:199264
	decreased osteoblast cell number	J:199264
	increased circulating adiponectin level	J:199264
	increased trabecular bone volume	J:199264